Skip to content

Author

Kai-Hang Yiu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis : A Target Trial Emulation.

BACKGROUND Whether direct oral anticoagulants (DOACs) are a safe and effective alternative to warfarin in patients with atrial fibrillation and mitral stenosis (AF-MS) remains controversial. OBJECTIVE To evaluate the effectiveness and safety of DOACs versus warfarin in patients with AF-MS. DESIGN Observational cohort study using target trial emulation. SETTING Population-wide insurance claims data in Taiwan. PARTICIPANTS Patients diagnosed with AF-MS and prescribed either DOACs or warfarin between 1 January 2011 and 31 December 2021 were included in the study. INTERVENTION DOACs or warfarin. MEASUREMENTS Absolute risk differences (RDs) and risk ratios (RRs) at 1 year and 5 years of follow-up for ischemic stroke, systemic embolism, composite stroke, myocardial infarction (MI), intracranial hemorrhage, gastrointestinal bleeding, bleeding at other critical sites, and all-cause death. RESULTS Compared with warfarin, DOACs were associated with an increased risk for ischemic stroke (RD, 4.97 percentage points [95% CI, 1.27 to 8.57 percentage points]; RR, 1.22 [CI, 1.05 to 1.41]) and composite stroke (RD, 5.56 percentage points [CI, 1.77 to 8.97 percentage points]; RR, 1.23 [CI, 1.07 to 1.42]) and a decreased risk for MI (RD, -1.61 percentage points [CI, -3.17 to -0.03 percentage points]; RR, 0.61 [CI, 0.37 to 0.99]) at the 1-year follow-up. Rivaroxaban increased the risk for ischemic stroke during both short- and long-term follow-up periods. The 2 groups did not differ in risks for bleeding or all-cause death. LIMITATION Limited sample size, lack of detailed information on MS severity, and lack of international normalized ratio measurements. CONCLUSION In Asian patients with AF-MS, DOACs were associated with an increased 1-year risk for stroke but a decreased risk for MI compared with warfarin. PRIMARY FUNDING SOURCE Research Grants Council of Hong Kong.

Yu Yang, Chin-Yao Shen, M. Cheng et al. · 0 citations
Aug 2026

MolADR: Multi-Scale Complementary Learning of Dual-Granularity Molecules and Knowledge Graphs for ADR Prediction in Drug Combinations

With the increasing use of multiple medications in clinical practice, accurate and interpretable prediction of organ-level adverse drug reactions (ADRs) induced by drug combinations is essential for drug safety assessment and precision medicine. Existing knowledge graph (KG)-based methods primarily model biomedical associations but leave direct structure-level interactions within drug pairs undercharacterized, while molecular representation methods often rely on whole-molecule or latent substructure encodings, offering limited chemically meaningful evidence for ADR risks. This study proposes MolADR, a multiscale complementary learning framework that integrates GNN-based KG learning with dual-granularity molecular cross-attention modeling to combine macro-level biomedical associations with microlevel molecular interaction cues. Under an emerging-drug setting, MolADR achieves PR-AUC scores of 81.17 ± 3.97, 84.04 ± 4.67, and 74.37 ± 9.90 on three data sets, consistently outperforming state-of-the-art baselines, with further analyses supporting its robustness and suggesting its ability to highlight chemically plausible atoms and functional groups for organ-level ADR prediction.

Yifan Qi, Q. Ren, Chen-Xu Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.